Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1998 1
2004 1
2012 1
2013 1
2014 1
2015 2
2016 3
2017 1
2018 2
2019 1
2020 2
2021 18
2022 21
2023 21
2024 25
2025 19

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

96 results

Results by year

Filters applied: . Clear all
Page 1
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
Kimball AB, Jemec GBE, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG, Paul C, Giamarellos Bourboulis EJ, Villani AP, Schwinn A, Ruëff F, Pillay Ramaya L, Reich A, Lobo I, Sinclair R, Passeron T, Martorell A, Mendes-Bastos P, Kokolakis G, Becherel PA, Wozniak MB, Martinez AL, Wei X, Uhlmann L, Passera A, Keefe D, Martin R, Field C, Chen L, Vandemeulebroecke M, Ravichandran S, Muscianisi E. Kimball AB, et al. Lancet. 2023 Mar 4;401(10378):747-761. doi: 10.1016/S0140-6736(23)00022-3. Epub 2023 Feb 3. Lancet. 2023. PMID: 36746171 Clinical Trial.
BACKGROUND: Few therapeutic options are available for patients with moderate-to-severe hidradenitis suppurativa. We aimed to assess the efficacy of secukinumab in patients with moderate-to-severe hidradenitis suppurativa in two randomised trials. ... …
BACKGROUND: Few therapeutic options are available for patients with moderate-to-severe hidradenitis suppurativa. We aimed to a …
Hidradenitis suppurativa.
Sabat R, Alavi A, Wolk K, Wortsman X, McGrath B, Garg A, Szepietowski JC. Sabat R, et al. Lancet. 2025 Feb 1;405(10476):420-438. doi: 10.1016/S0140-6736(24)02475-9. Epub 2025 Jan 22. Lancet. 2025. PMID: 39862870 Free article. Review.
Hidradenitis suppurativa is a chronic inflammatory disease characterised by painful, deep-seated nodules, abscesses, and draining tunnels in the skin of axillary, inguinal, genitoanal, or inframammary areas. In recent years, the body of knowledge in hidradenitis …
Hidradenitis suppurativa is a chronic inflammatory disease characterised by painful, deep-seated nodules, abscesses, and drain …
IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial.
Ackerman L, Acloque G, Bacchelli S, Schwartz H, Feinstein BJ, La Stella P, Alavi A, Gollerkeri A, Davis J, Campbell V, McDonald A, Agarwal S, Karnik R, Shi K, Mishkin A, Culbertson J, Klaus C, Enerson B, Massa V, Kuhn E, Sharma K, Keaney E, Barnes R, Chen D, Zheng X, Rong H, Sabesan V, Ho C, Mainolfi N, Slavin A, Gollob JA. Ackerman L, et al. Nat Med. 2023 Dec;29(12):3127-3136. doi: 10.1038/s41591-023-02635-7. Epub 2023 Nov 13. Nat Med. 2023. PMID: 37957373 Free PMC article. Clinical Trial.
Toll-like receptor-driven and interleukin-1 (IL-1) receptor-driven inflammation mediated by IL-1 receptor-associated kinase 4 (IRAK4) is involved in the pathophysiology of hidradenitis suppurativa (HS) and atopic dermatitis (AD). KT-474 (SAR444656), an IRAK4 degrade …
Toll-like receptor-driven and interleukin-1 (IL-1) receptor-driven inflammation mediated by IL-1 receptor-associated kinase 4 (IRAK4) is inv …
Brepocitinib, Zimlovisertib, and Ropsacitinib in Hidradenitis Suppurativa.
Kimball AB, Peeva E, Forman S, Moiin A, Khattri S, Porter ML, Mangold AR, Ghosh P, Banfield C, Oemar B. Kimball AB, et al. NEJM Evid. 2024 Mar;3(3):EVIDoa2300155. doi: 10.1056/EVIDoa2300155. Epub 2024 Feb 9. NEJM Evid. 2024. PMID: 38335032 Clinical Trial.
BACKGROUND: Hidradenitis suppurativa (HS) is a debilitating, inflammatory skin disease with limited treatment options and partially understood pathophysiology. ...
BACKGROUND: Hidradenitis suppurativa (HS) is a debilitating, inflammatory skin disease with limited treatment options and part …
Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study.
Kirby JS, Okun MM, Alavi A, Bechara FG, Zouboulis CC, Brown K, Santos LL, Wang A, Bibeau KB, Kimball AB, Porter ML. Kirby JS, et al. J Am Acad Dermatol. 2024 Mar;90(3):521-529. doi: 10.1016/j.jaad.2023.10.034. Epub 2023 Oct 21. J Am Acad Dermatol. 2024. PMID: 37871805 Free article. Clinical Trial.
BACKGROUND: Janus kinase 1 inhibition may alleviate hidradenitis suppurativa (HS)-associated inflammation and improve symptoms. OBJECTIVE: To assess efficacy and safety of povorcitinib (selective oral Janus kinase 1 inhibitor) in HS. ...
BACKGROUND: Janus kinase 1 inhibition may alleviate hidradenitis suppurativa (HS)-associated inflammation and improve symptoms …
Medical Management of Hidradenitis Suppurativa with Non-Biologic Therapy: What's New?
Ghanian S, Yamanaka-Takaichi M, Naik HB, Alavi A. Ghanian S, et al. Am J Clin Dermatol. 2022 Mar;23(2):167-176. doi: 10.1007/s40257-021-00667-8. Epub 2022 Jan 6. Am J Clin Dermatol. 2022. PMID: 34990004 Free PMC article. Review.
Hidradenitis suppurativa (HS) is a severe chronic relapsing inflammatory disorder of the hair follicle unit that can cause painful abscesses, nodules, tunnels, and tracts in intertriginous parts of the body. ...
Hidradenitis suppurativa (HS) is a severe chronic relapsing inflammatory disorder of the hair follicle unit that can cause pai …
Histopathology of Hidradenitis Suppurativa: A Systematic Review.
Smith SDB, Okoye GA, Sokumbi O. Smith SDB, et al. Dermatopathology (Basel). 2022 Jul 14;9(3):251-257. doi: 10.3390/dermatopathology9030029. Dermatopathology (Basel). 2022. PMID: 35892482 Free PMC article. Review.
Hidradenitis suppurativa (HS) is a chronic inflammatory scarring disease felt to be related to occlusion of the hair follicle unit in intertriginous areas. ...
Hidradenitis suppurativa (HS) is a chronic inflammatory scarring disease felt to be related to occlusion of the hair follicle …
Systemic associations of hidradenitis suppurativa.
Kohorst JJ, Kimball AB, Davis MD. Kohorst JJ, et al. J Am Acad Dermatol. 2015 Nov;73(5 Suppl 1):S27-35. doi: 10.1016/j.jaad.2015.07.055. J Am Acad Dermatol. 2015. PMID: 26470611 Review.
Hidradenitis suppurativa (HS) is a progressive, inflammatory disease that affects mostly young women and appears to be caused by inflammation of hair follicles in areas of friction in the body (eg, the axillae, groin, perineum, and medial aspects of the thighs). ...
Hidradenitis suppurativa (HS) is a progressive, inflammatory disease that affects mostly young women and appears to be caused …
Inpatient Management of Hidradenitis Suppurativa: A Delphi Consensus Study.
Needham M, Pichardo R, Alavi A, Chang AY, Daveluy S, DeNiro KL, Dewan A, Eshaq M, Fox L, Hsiao JL, Kaffenberger BH, Kirby JS, Kroshinsky D, Ortega-Loayza AG, Manusco JB, Micheletti RG, Mostaghimi A, Nelson CA, Pasieka HB, Porter ML, Resnik BI, Sayed CJ, Shi VY, Shields BE, Strowd LC. Needham M, et al. Cutis. 2024 Jun;113(6):251-254. doi: 10.12788/cutis.1027. Cutis. 2024. PMID: 39082985
Inpatient hospitalization of individuals with hidradenitis suppurativa (HS) has increased. Inpatient services may not be familiar enough with this disease to understand how to manage severe HS and/or HS flares. ...
Inpatient hospitalization of individuals with hidradenitis suppurativa (HS) has increased. Inpatient services may not be famil …
Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: a randomized double-blind placebo-controlled clinical trial.
Alavi A, Prens EP, Kimball AB, Frew JW, Krueger JG, Mukhopadhyay S, Gao H, Ranganathan U, Ivanoff NB, Hernandez Daly AC, Zouboulis CC. Alavi A, et al. Br J Dermatol. 2024 Sep 18;191(4):508-518. doi: 10.1093/bjd/ljae144. Br J Dermatol. 2024. PMID: 38576350 Clinical Trial.
BACKGROUND: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with a considerable disease burden. ...Secondary endpoints were the absolute change from baseline in the International Hidradenitis Suppurativa Severity Score System (IHS4 …
BACKGROUND: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with a considerable disease burden. ...Second …
96 results